Where others have failed will Atl1102 succeed ?, page-199

Antisense Therapeutics (ASX:ANP) closes in on clinical supplies for muscular dystrophy trial

- Antisense Therapeutics (ANP) has moved a step closer towards manufacturing the first batch of clinical supplies for its muscular dystrophy treatment clinical trial
- Through its North American supply chain, the ASX-lister has been able to formulate ATL1102's active pharmaceutical ingredient, API, into an injectable product for use in clinical trials
- The product is currently undergoing finished product release testing for clinical use, with results anticipated next month according to ANP
- The drug is hoped to aid non-ambulant Duchenne muscular dystrophy patients by targeting inflammation that aggravates muscle fibre damage
- Antisense Therapeutics shares are up five per cent following the announcement, trading at 21 cents
http://themarketherald.com.au/antisense-therapeutics-asxanp-closes-in-on-clinical-supplies-for-muscular-dystrophy-trial-2021-05-26/?utm_source=threadview%20tmh%20widget&utm_medium=widget&utm_campaign=threadview%20tmh%20widget%20%7C%20click&utm_content=https://hotcopper.com.au/threads/widely-fully-financed-companies.5271206/page-18#post-53416677&utm_term=blank